Início › Câncer de Pulmão › Pensilvânia › Pittsburgh
Ensaios clínicos de Câncer de Pulmão em Pittsburgh, PA
23 estudos para Câncer de Pulmão estão buscando participantes em locais em Pittsburgh e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecrutandoFase 3
- Bryn Mawr Hospital, Bryn Mawr · a 11 mi de distância
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RecrutandoFase 1/2
- Allegheny Research Institute (Melanoma/NSCLC), Pittsburgh
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecrutandoFase 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- e mais 11
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecrutandoFase 3
- Bryn Mawr Hospital, Bryn Mawr · a 11 mi de distância
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecrutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Recrutando
- UPMC Hillman Cancer Center, Pittsburgh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecrutandoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
- Bryn Mawr Hospital, Bryn Mawr · a 11 mi de distância
- UPMC Hillman Cancer Center - Monroeville, Monroeville · a 11 mi de distância
- e mais 1
A Registry for People With Lung Cancer
RecrutandoEstudo observacional
- ALLEGHENY HEALTH NETWORK (Data Collection Only), Pittsburgh
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RecrutandoFase 2
- Research Site, Pittsburgh
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecrutandoFase 2/3
- West Penn Allegheny Health, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecrutandoFase 1/2
- Allegheny Health Network, Pittsburgh
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RecrutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecrutandoFase 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RecrutandoFase 3
- Allegheny Cancer Center, Pittsburgh
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RecrutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
RecrutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecrutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecrutandoFase 2
- Allegheny General Hospital, Natrona Heights · a 19 mi de distância
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecrutandoFase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecrutandoFase 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC-Mercy Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- e mais 11
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2/3
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- e mais 9
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RecrutandoEstudo observacional
- Allegheny Health Network, Pittsburgh
Detection of Genetic Markers of Lung Cancer
RecrutandoEstudo observacional
- Hillman Cancer Center, Pittsburgh
Ensaios de Câncer de Pulmão em outras cidades
- Houston, TX78 estudos
- Boston, MA62 estudos
- New York City, NY60 estudos
- Los Angeles, CA45 estudos
- Arlington, VA41 estudos
- Washington, DC41 estudos
- Chicago, IL41 estudos
- Baltimore, MD40 estudos
- Nashville, TN40 estudos
- St. Louis, MO39 estudos
- Columbus, OH37 estudos
- Philadelphia, PA36 estudos
Outros estudos em Pittsburgh
- Câncer de Pulmão de Não Pequenas Células48 estudos
- Câncer (todos os tipos)41 estudos
- Câncer de Mama39 estudos
- Câncer Colorretal32 estudos
- Câncer Metastático31 estudos
- Melanoma31 estudos
- Câncer de Ovário30 estudos
- Câncer Endometrial23 estudos
- Câncer de Próstata23 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço22 estudos
- Acidente Vascular Cerebral22 estudos
- Depressão22 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.